




# Beyond the validation of a biomarker in the periodic catatonia



de Billy C, Jeanjean L C, Mainberger O, Obrecht A, Clauss J M E, Schorr B, de Sousa P L, Lamy J, Noblet V, Landré L, Berna F, Sauleau E A, Foucher JR



Dr Clément de BILLY - MD  
Non invasive Neuromodulation center of  
Strasbourg



**Neuromodulation in  
psychiatry**  
**February 10th 2023**  
Forum amphi 301  
Strasbourg



# Conflict of interest



- None

FEBRUARY 10TH


NEUREX : NEUROMODULATION IN PSYCHIATRY

# Focus on the periodic catatonia


- Polymorphic psychosis with psychomotor impairment
- Progressive remittent bipolar evolution
- Diagnosis of phenotype ! (lifetime)
- High heritability
- Neuroimaging group studies: 2 ROIs



Walther et coll.  
*Schizophr Bull* 2017




Foucher et coll.  
*Neuropsychopharmacol  
Biol Psychiatry* 2018



de CRESPIN de BILLY, et al.  
*The Lancet Psychiatry*, 2021

# Cerebral blood flow measurements



- rCBF via MRI (ASL no contrast agent)
- Images at rest and during tasks
- 3x2 measures (TE 9.7ms and 21 ms)
- 2 ROIs: L-PM and/or L-SMA
- Single subject data
- Compared to 40 Controls database

*Foucher et al., Journal of Magnetic Resonance Imaging, 2011*



# A bayesian statistical model



- modelling of an estimation of  $Se$  and  $Sp$
- Possibility of repetitive analysis
  - Bayesian Updating ability !
- Uses of prior data
- More intuitive representation of the result
  - Belief in a result


# Results

High Accuracy

High Repetability

Reliable  
measurement





**Biomarker ROC Curve**

## Results

- 9 CP and 26 non-CP in a proof of concept study
- Se of 98 % and Sp of 88 %
- Non informative prior

*Foucher JR, de Billy C, et al. Neuropsychobiology. 2019*



# Properties



**Sp/other forms of catatonia!**



**Sensitive to other motor  
Impairment**



# Replication of results

Analysis with a new prior (Weighted data from previous study)

Inclusion of 13 CP and 8 non-CP

Se of 77% and Sp of 78%

Patients with more unclear diagnosis, diagnostic corrections

*Ibrahim JG et al. Stat Med. 2015.*

# Update of the biomarker

Non informative prior with full data

Update of the Bayesian model

Estimation of the biomarker potential

Correctly used: Se to 82% and Sp to 98%

# Conclusion

Before Test	In case of SSD	After Test
14,2	PPV	73
14,2	NPV	3

## Biomarker sensitive and specific

- Good PPV and NPV if associated with clinical examination

## Replication of results in further studies

- model allowing repeated analysis using weighted past data

# Perspectives



More accurate diagnosis for boundary patients



Genetic studies with follow-up of carrier parents?



Phenotype scaffolding using a reverse phenotyping approach (ASD cases)



Basic and therapeutic research

# SPECIAL THANKS TO



Laura-Adela HARSAN  
Director of the IMIS team



Paulo LOUREIRO de SOUSA  
MRI Physicist




Dr Jack FOUCHER  
MD. PhD in psychiatry and  
neurology



Pr Frédéric de BLAY  
director of the physiology  
department



Pr Bernard GENY  
director of the physiology  
service



The background is a dark blue gradient. In the four corners, there are decorative white line art elements resembling circuit boards or neural networks, with lines and small circles connecting them.

# THANK YOU FOR YOUR ATTENTION

FOR ANY INFORMATION :

Dr Clément de CRESPIN de BILLY

[clement.de-billy@chru-strasbourg.fr](mailto:clement.de-billy@chru-strasbourg.fr)

+33.3.88.11.69.21